Cardiovascular protection by β-blockade in hypertensive haemodialysis patients: the Hypertension in Haemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial.
This was an open-label trial of atenolol vs lisinopril administered three times per week post-dialysis in patient with hypertension and left ventricular hypertrophy. The atenolol treated group had lower cardiovascular morbidity and all-cause hospitalizations.
:
Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.
High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Trial Results Hemodialysis Hypertension Source Type: research
More News: Atenolol | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Dialysis | Endocrinology | Heart | Hemodiafiltration | Hemodialysis | Hypertension | Lisinopril | Urology & Nephrology